Literature DB >> 10369861

High level expression of expanded full-length ataxin-3 in vitro causes cell death and formation of intranuclear inclusions in neuronal cells.

B O Evert1, U Wüllner, J B Schulz, M Weller, P Groscurth, Y Trottier, A Brice, T Klockgether.   

Abstract

Spinocerebellar ataxia type 3 (SCA3) is caused by a CAG/polyglutamine repeat expansion in the SCA3 gene. To analyse the pathogenic mechanisms in SCA3, we have generated ataxin-3-expressing rat mesencephalic CSM14.1 cells. In these cells, a post-mitotic neuronal phenotype is induced by temperature shift. The isolated stable cell lines provided high level expression of non-expanded (Q23) or expanded (Q70) human full-length ataxin-3. CSM14.1 cells expressing the expanded full-length ataxin-3 developed nuclear inclusion bodies, strong indentations of the nuclear envelope and cytoplasmic vacuolation. These ultrastructural alterations were present prior to a significantly decreased viability of neuronally differentiated cells expressing expanded ataxin-3. The observed spontaneous cell death did not correlate with formation of intranuclear inclusions and was not apoptotic by ultrastructural analysis. No increased susceptibility to staurosporine-induced apoptosis was found for the expanded or non-expanded ataxin-3-expressing cell lines. These data show that high level expression of expanded full-length ataxin-3 in a neuron-like cell line generates ultrastructural alterations of SCA3 pathogenesis and results in increased spontaneous non-apoptotic cell death.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10369861     DOI: 10.1093/hmg/8.7.1169

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  24 in total

Review 1.  Toward understanding Machado-Joseph disease.

Authors:  Maria do Carmo Costa; Henry L Paulson
Journal:  Prog Neurobiol       Date:  2011-11-23       Impact factor: 11.685

Review 2.  The role of deubiquitinating enzymes in apoptosis.

Authors:  Suresh Ramakrishna; Bharathi Suresh; Kwang-Hyun Baek
Journal:  Cell Mol Life Sci       Date:  2010-08-21       Impact factor: 9.261

Review 3.  Machado-Joseph disease/spinocerebellar ataxia type 3.

Authors:  Henry Paulson
Journal:  Handb Clin Neurol       Date:  2012

Review 4.  Non-apoptotic cell death in animal development.

Authors:  Lena M Kutscher; Shai Shaham
Journal:  Cell Death Differ       Date:  2017-02-17       Impact factor: 15.828

5.  Cerebellar TMS in treatment of a patient with cerebellar ataxia: evidence from clinical, biomechanics and neurophysiological assessments.

Authors:  Faranak Farzan; Yunfen Wu; Brad Manor; Elana M Anastasio; Matthew Lough; Vera Novak; Patricia E Greenstein; Alvaro Pascual-Leone
Journal:  Cerebellum       Date:  2013-10       Impact factor: 3.847

Review 6.  Nuclear transport, oxidative stress, and neurodegeneration.

Authors:  Vivek P Patel; Charleen T Chu
Journal:  Int J Clin Exp Pathol       Date:  2011-02-28

7.  Compromised mitochondrial complex II in models of Machado-Joseph disease.

Authors:  Mário N Laço; Catarina R Oliveira; Henry L Paulson; A Cristina Rego
Journal:  Biochim Biophys Acta       Date:  2011-10-20

8.  Analysis of the role of heat shock protein (Hsp) molecular chaperones in polyglutamine disease.

Authors:  Y Chai; S L Koppenhafer; N M Bonini; H L Paulson
Journal:  J Neurosci       Date:  1999-12-01       Impact factor: 6.167

9.  Inflammatory genes are upregulated in expanded ataxin-3-expressing cell lines and spinocerebellar ataxia type 3 brains.

Authors:  B O Evert; I R Vogt; C Kindermann; L Ozimek; R A de Vos; E R Brunt; I Schmitt; T Klockgether; U Wüllner
Journal:  J Neurosci       Date:  2001-08-01       Impact factor: 6.167

10.  Huntington's disease is a four-repeat tauopathy with tau nuclear rods.

Authors:  Marta Fernández-Nogales; Jorge R Cabrera; María Santos-Galindo; Jeroen J M Hoozemans; Isidro Ferrer; Annemieke J M Rozemuller; Félix Hernández; Jesús Avila; José J Lucas
Journal:  Nat Med       Date:  2014-07-20       Impact factor: 53.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.